The stock’s performance reflects intense market anticipation, building on a year that has already seen the company’s valuation triple. Bempikibart, the focus of the study, targets patients suffering from severe or very severe forms of alopecia areata, an autoimmune condition characterized by unpredictable hair loss. The biotech firm’s ability to deliver positive clinical results will be a decisive factor for shareholders who have fueled the stock's aggressive climb throughout the year.